3Scan, a San Francisco, CA-based computational pathology services platform, raised $14m in Series B financing.
The round was led by existing investors Lux Capital and Data Collective, with participation from the investment arm of one of the top U.S. research hospitals, prior backer Dolby Family Ventures, and new investors OS Fund, Comet Labs and Breakout Ventures.
The company intends to use the funds to expand its position in the pre-clinical drug discovery market, as well as to continue to build out its image processing and image analysis software stack.
Founded in 2010 by Todd Huffman (CEO), Megan Klimen (COO), Matthew Goodman (CTO), and Cody Daniel (Chief Engineer), 3Scan allows pharma and university researchers to examine tissue by leveraging high precision robotics that sections entire blocks of tissue. Customers send their tissue samples to 3Scan’s lab, where the tissue is stained to make the areas of interest visible, embedded in a resin or wax, and placed onto the company’s patented Knife Edge Scanning Microscopes (KESM) to generate thousands of sections, and corresponding images, from a single block of tissue.
These thousands of sections, each of which is equivalent to a traditional slide, can be used individually, or stacked together to examine the tissue in 3D.
Once imaging is complete, 3Scan uses their custom software to allow customers to scan through these sections looking for cells or other regions of interest and also analyzes the full 3D structure of the sample.